<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Late-stage pipelines and regulatory momentum create licensing and partnership potentialDublin, Sept. 09, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6274245/obstructive-sleep-apnea-competitive-landscape?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=79bxkz&amp;utm_campaign=2346364+-+2026+Obstructive+Sleep+Apnea+(OSA)+Competitive+Landscape+and+Clinical+Trial+Analysis+-+18%2b+Companies+Advance+New+OSA+Therapies&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Obstructive Sleep Apnea - Competitive Landscape and Clinical Trial Analysis, 2026">"Obstructive Sleep Apnea - Competitive Landscape and Clinical Trial Analysis, 2026"</a> has been added to ResearchAndMarkets.com's offering. The report delivers a comprehensive global assessment of more than 18 companies and over 20 marketed and investigational drugs within the obstructive sleep apnea therapeutics market. The report evaluates products by development stage, product type, route of administration, and molecule type while also examining inactive pipeline assets, unmet medical needs, clinical trial activity, strategic partnerships, licensing agreements, and acquisitions. Global Obstructive Sleep Apnea Market Overview Obstructive sleep apnea (OSA) is a sleep-related breathing disorder characterized by recurrent partial or complete upper-airway obstruction during sleep. These episodes result in apnea or hypopnea, intermittent oxygen desaturation, carbon dioxide accumulation, sleep fragmentation, and recurrent arousals. OSA is associated with excessive daytime sleepiness, fatigue, cognitive impairment, and elevated cardiovascular and metabolic risk. Disease development reflects interactions between upper-airway anatomy, neuromuscular function, and ventilatory control. Key risk factors include obesity, older age, male sex, increased neck circumference, craniofacial abnormalities, menopause, family history, smoking, and nasal congestion. Recurrent intermittent hypoxia and fragmented sleep may increase sympathetic activity, oxidative stress, and inflammation. Diagnosis typically combines clinical assessment with objective sleep testing. Overnight polysomnography remains the standard diagnostic method, while home sleep apnea testing may be appropriate for selected patients. Disease severity is commonly classified using the apnea-hypopnea index: 5 to fewer than 15 events per hour indicates mild OSA, 15 to fewer than 30 indicates moderate OSA, and 30 or more indicates severe OSA. Current obstructive sleep apnea treatment options include continuous positive airway pressure, bilevel positive airway pressure, weight management, mandibular advancement devices, pharmacotherapy, and surgical intervention. Treatment selection depends on disease severity, upper-airway anatomy, comorbidities, clinical phenotype, patient preference, and tolerance. Pharmaceutical innovation is increasingly focused on obesity-related disease, neuromuscular dysfunction, ventilatory instability, and other underlying biological mechanisms. Recent Obstructive Sleep Apnea Pipeline and Regulatory Developments <ul><li>In July 2026, the U.S. Food and Drug Administration accepted Apnimed's New Drug Application for AD109, comprising aroxybutynin 2.3 mg and atomoxetine 75 mg, for adults with obstructive sleep apnea. The FDA assigned a Prescription Drug User Fee Act target action date of February 28, 2027.</li><li>In June 2026, Incannex Healthcare announced that the United States Patent and Trademark Office had granted a patent titled "Compositions and Methods of Treatment for Obstructive Sleep Apnea."</li><li>In May 2026, Apnimed announced peer-reviewed publications covering AD109 and results from the Phase III SynAIRgy trial, together with a mechanistic review of its neuromuscular approach.</li><li>In December 2025, the FDA granted Fast Track designation to Incannex Healthcare's IHL-42X, an oral fixed-dose combination candidate for OSA.</li><li>In May 2025, Mosanna Therapeutics secured USD 80 million in Series A financing to support development of MOS118, including advancement through Phase II clinical trials.</li><li>In January 2025, the FDA cleared Mineralys Therapeutics' Investigational New Drug application for a Phase II trial of lorundrostat in patients with moderate-to-severe OSA and hypertension.</li></ul> Marketed Obstructive Sleep Apnea Therapy Eli Lilly and Company: Zepbound Zepbound, or tirzepatide, is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company. Its effects on appetite, food intake, and body weight may reduce obesity-related upper-airway obstruction and the frequency of apnea and hypopnea events. The FDA approved tirzepatide in December 2024 for moderate-to-severe OSA in adults with obesity, making it the first medication specifically approved by the agency for OSA. Selected Obstructive Sleep Apnea Pipeline Therapies Apnimed: AD109 AD109 is an investigational once-nightly oral combination of aroxybutynin and atomoxetine. It is designed to improve oxygenation during sleep by targeting neuromuscular mechanisms associated with upper-airway collapse. If approved, AD109 could provide a pharmacological alternative within a treatment landscape historically dominated by mechanical and procedural interventions. Eli Lilly and Company: Orforglipron Orforglipron is a once-daily oral, non-peptide, small-molecule GLP-1 receptor agonist. The candidate is designed to support weight reduction and glucose regulation without the food and water restrictions associated with some oral peptide therapies. Discovered by Chugai Pharmaceutical and licensed to Lilly in 2018, orforglipron is being evaluated in Phase III development for sleep apnea. Incannex Healthcare: IHL-42X IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide. The candidate is designed to target upper-airway dysfunction and ventilatory control instability through complementary mechanisms. Development is focused on reducing apnea and hypopnea frequency, as measured by the apnea-hypopnea index. IHL-42X is currently in Phase II/III development for obstructive sleep apnea. Mosanna Therapeutics: MOS118 MOS118 is an investigational intranasal small-molecule therapy administered at bedtime. It is intended to modulate neuromuscular control of the upper airway and reduce airway collapse during sleep. The non-invasive pharmacological candidate is currently undergoing Phase I development for OSA. Commercial, Competitive, and Clinical Trial Analysis The obstructive sleep apnea competitive landscape report provides company and product comparisons by therapeutic approach, technology, molecule type, route of administration, and clinical development stage. Its commercial assessment examines company-to-company partnerships, industry-academic collaborations, licensing transactions, acquisitions, and deal-value trends. The clinical trial assessment evaluates studies by status, development phase, therapeutic category, participant age, enrollment, completion year, and endpoint status. Trial design analysis covers allocation, interventional model, masking, and recruitment status. Sponsor and geographic assessments compare leading sponsors, development stages, countries conducting OSA clinical trials, and the distribution of therapies by market. Report Coverage <ul><li>Global obstructive sleep apnea company analysis</li><li>Marketed and emerging therapy assessment</li><li>Drug pipeline analysis by development stage</li><li>Inactive and discontinued product assessment</li><li>Clinical trial and study design analysis</li><li>Sponsor and geographic analysis</li><li>Collaboration, licensing, partnership, and acquisition analysis</li><li>Unmet needs and emerging treatment trends</li></ul> Key Companies Covered Leading companies evaluated in the report include Eli Lilly and Company, Apnimed, Amgen, Mosanna Therapeutics, Mineralys Therapeutics, Shionogi-Apnimed Sleep Science, Incannex Healthcare, Novo Nordisk, Gan &amp; Lee Pharmaceuticals, Hangzhou Sciwind Biosciences, Hengrui Pharma, and Kailera Therapeutics. Key Obstructive Sleep Apnea Products Products featured in the analysis include Zepbound, AD109, eloralintide, orforglipron, maridebart cafraglutide, MOS118, lorundrostat, SASS-001, SASS-002 (sulthiame), IHL-42X, NNC0487-0111, GZR18, XW003, and ribupatide injection, also identified as HRS9531 and KAI-9531 outside Greater China. Strategic Questions Addressed <ul><li>How many companies and drug candidates are active in the obstructive sleep apnea market?</li><li>Which emerging OSA therapies are in early-, mid-, and late-stage clinical development?</li><li>What mechanisms, molecule types, and drug-delivery technologies are shaping the OSA pipeline?</li><li>Which clinical trials are ongoing, and what are their design characteristics and development statuses?</li><li>What regulatory designations have been granted to marketed and emerging therapies?</li><li>Which collaborations, licensing agreements, mergers, and acquisitions are influencing the competitive landscape?</li><li>How are developers addressing the limitations of existing obstructive sleep apnea treatments?</li></ul> By combining therapeutic, clinical, regulatory, and commercial intelligence, the report provides a detailed view of the evolving obstructive sleep apnea treatment landscape and the companies positioned to influence future market development. A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Eli Lilly and Company</li><li>Apnimed</li><li>Amgen</li><li>Mosanna Therapeutics</li><li>Mineralys Therapeutics Inc.</li><li>Shionogi-Apnimed Sleep Science, LLC</li><li>Incannex Healthcare Ltd.</li><li>Novo Nordisk</li><li>Gan &amp; lee pharmaceuticals</li><li>Hangzhou Sciwind Biosciences Co., Ltd.</li><li>Hengrui Pharma</li><li>Kailera Therapeutics</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6274245/obstructive-sleep-apnea-competitive-landscape?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=79bxkz&amp;utm_campaign=2346364+-+2026+Obstructive+Sleep+Apnea+(OSA)+Competitive+Landscape+and+Clinical+Trial+Analysis+-+18%2b+Companies+Advance+New+OSA+Therapies&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/d94gn2</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NTI3Mzc4NzYtZWQ1MC00YTg4LTg0MjQtYzZmMGMwN2E0ZTg3LTEwMjY3MzctMjAyNi0wOS0wOS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

2026 Obstructive Sleep Apnea (OSA) Competitive Landscape and Clinical Trial Analysis - 18+ Companies Advance New OSA Therapies

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn